Tech Company Financing Transactions
VitriVax Funding Round
On 10/14/2025, VitriVax raised $9.9 million in financing from Bill & Melinda Gates Foundation.
Transaction Overview
Company Name
Announced On
10/14/2025
Transaction Type
Debt
Amount
$9,900,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support the scale-up of VitriVax's Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
3415 Colorado Ave.
Boulder, CO 80303
USA
Boulder, CO 80303
USA
Phone
Undisclosed
Website
Email Address
Overview
VitriVax is a formulation technology company engineering innovative solutions to maximize global accessibility and utility of human and animal vaccines -- vaccines that save lives and protect our world from preventable disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Raider
Chief Medical Officer
Romulo Colindres
Chief Technical Officer
Bryan Steadman
Co-Founder
Robert Garcea
Co-Founder
Theodore Randolph
VP - Finance
Kyle Stults
Browse more venture capital transactions:
Prev: 10/14/2025: Basis Theory venture capital transaction
Next: 10/14/2025: ABK Biomedical venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs